(2,2,2-trifluoro-ethyl)-guanidine | 461-36-9

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (2,2,2-trifluoro-ethyl)-guanidine
• 英文别名: 1,1,1-Trifluor-2-guanidino-aethan；(2,2,2-Trifluor-aethyl)-guanidin；2-(2,2,2-Trifluoroethyl)guanidine
• CAS: 461-36-9
• 化学式: C₃H₆F₃N₃
• 分子量: 141.096
• InChiKey: BZGIGIXURRLWCE-UHFFFAOYSA-N

物化性质

• 沸点：
  104.3±50.0 °C(Predicted)
• 密度：
  1.51±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  皮考林乙酸乙酯 、 (2,2,2-trifluoro-ethyl)-guanidine 在 potassium carbonate 作用下， 以 乙醇 为溶剂， 生成
  参考文献：
  名称：

  Discovery of 2-Pyridylpyrimidines as the First Orally Bioavailable GPR39 Agonists

  摘要：

  The identification of highly potent and orally bioavailable GPR39 agonists is reported. Compound 1, found in a phenotypic screening campaign, was transformed into compound 2 with good activity on both the rat and human GPR39 receptor. This compound was further optimized to improve ligand efficiency and pharmacokinetic properties to yield GPR39 agonists for the potential oral treatment of type 2 diabetes. Thus, compound 3 is the first potent GPR39 agonist (EC(50)s <= 1 nM for human and rat receptor) that is orally bioavailable in mice and robustly induced acute GLP-1 levels.

  DOI：

  10.1021/ml500240d
• 作为产物：
  描述：

  1-硝基-2-(2,2,2-三氟乙基)胍 在 钯 、 溶剂黄146 作用下， 生成 (2,2,2-trifluoro-ethyl)-guanidine
  参考文献：
  名称：

  2,2,2-Trifluoroethylnitroguanidine¹

  摘要：

  DOI：

  10.1021/ja01615a078

文献信息

• Improved method for the preparation of guanidines
  作者：Kyoung Soon Kim、Ligang Qian

  DOI：10.1016/s0040-4039(00)61537-x

  日期：1993.11

  Use of N,N′-di-(tert-butoxycarbonyl)thiourea 1 in the presence of mercuric chloride provides a very efficient method for the bis-Boc protected guanidine formation of the amino compounds which are highly deactivated either sterically or electronically.

  在氯化汞的存在下使用N，N'-二-（叔丁氧基羰基）硫脲1提供了一种非常有效的方法，用于双-Boc保护的氨基化合物的空间或电子高度失活的胍形成。
• Urethane protected derivatives of 1-guanylpyrazole for the mild and efficient preparation of guanidines
  作者：Michael S. Bernatowicz、Youling Wu、Gary R. Matsueda

  DOI：10.1016/s0040-4039(00)79163-5

  日期：1993.5

  Bis-urethane protected derivatives of 1-guanylpyrazole were prepared and found to readily react with relatively unreactive amines at room temperature to produce bis-protected guanidines in good yields. Simultaneous removal of both protecting groups from these products efficiently produced monosubstituted guanidines.
• Synthesis and evaluation of pyrazolo[1,5-b]pyridazines as selective cyclin dependent kinase inhibitors
  作者：Kirk L. Stevens、Michael J. Reno、Jennifer B. Alberti、Daniel J. Price、Laurie S. Kane-Carson、Victoria B. Knick、Lisa M. Shewchuk、Anne M. Hassell、James M. Veal、Stephen T. Davis、Robert J. Griffin、Michael R. Peel

  DOI：10.1016/j.bmcl.2008.09.069

  日期：2008.11

  A novel series of pyrazolo[1,5-b]pyridazines have been synthesized and identified as cyclin dependant kinase inhibitors potentially useful for the treatment of solid tumors. Modification of the hinge-binding amine or the C(2)- and C(6)-substitutions on the pyrazolopyridazine core provided potent inhibitors of CDK4 and demonstrated enzyme selectivity against VEGFR-2 and GSK3beta.
• Identification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X3/P2X2/3 antagonist for the treatment of pain
  作者：Alam Jahangir、Muzaffar Alam、David S. Carter、Michael P. Dillon、Daisy Joe Du Bois、Anthony P.D.W. Ford、Joel R. Gever、Clara Lin、Paul J. Wagner、Yansheng Zhai、Jeff Zira

  DOI：10.1016/j.bmcl.2009.01.097

  日期：2009.3

  The purinoceptor subtypes P2X(3) and P2X(2/3) have been shown to play a pivotal role in models of various pain conditions. Identification of a potent and selective dual P2X(3)/P2X(2/3) diaminopyrimidine antagonist RO-4 prompted subsequent optimization of the template. This paper describes the SAR and optimization of the diaminopyrimidine ring and particularly the substitution of the 2-amino group. The discovery of the highly potent and drug-like dual P2X(3)/P2X(2/3) antagonist RO-51 is presented. (C) 2009 Elsevier Ltd. All rights reserved.
• Douglas; Diamond; Studt, Arzneimittel-Forschung/Drug Research, 1978, vol. 28, # 8 A, p. 1435 - 1441
  作者：Douglas、Diamond、Studt、Mir、Alioto、Auyang、Burns、Cias、Darkes、Dodson、O'Connor、Santora、Tsuei、Zalipsky、Zimmerman

  DOI：——

  日期：——